A Phase II Trial on Osimertinib as a First-Line Treatment for <i>EGFR</i> Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study

Although this study did not meet the primary endpoint, osimertinib was tolerable for elderly patients with EGFR mutation-positive advanced non-small cell lung cancer. (Japan Registry of Clinical Trials [JRCT] ID number: jRCTs071180007).